Astellas To Close Two Facilities Of Just-Acquired OSI Of U.S.
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma says it will close two U.S. plants by next June as part of its plans to integrate units of OSI Pharmaceuticals, which it just acquired for $4 billion